NCT07224607 · RECRUITING

Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

This trial is testing whether shining near-infrared light on the forehead, using a handheld device, can improve thinking and memory in people with Mild Cognitive Impairment or mild Alzheimer's dementia. Researchers will measure executive function and look at blood markers tied to inflammation and brain cell damage. This is a Phase NA, or feasibility-stage study, meaning the goal is early evidence and safety data, not a proven treatment.

You may qualify if

  • Signed and dated informed consent form (either by subject or LAR)
  • Willingness and ability to comply with all study procedures
  • Age 55 to 89 years, inclusive
  • Clinical diagnosis of Mild Cognitive Impairment or mild dementia (CDR Global = 0-1; MoCA 16-25) due to probable Alzheimer's disease diagnosis
  • Ability to attend in-person sessions at Cedars-Sinai and adhere to weekly visits
  • Stable dose of Alzheimer's disease medications (e.g., donepezil, rivastigmine, memantine, galantamine) for at least 4 weeks prior to enrollment, if applicable

You're excluded if

  • Presence of significant neurological conditions other than AD (e.g., epilepsy, Parkinson, etc.)
  • History of Seizures
  • If patient holds neuroimaging showing space-occupying lesions
  • If patient holds imaging with Fazekas greater than or equal to 3, more than 2 lacunar infarcts, and/or more than 5 microhemorrhages
  • Current pregnancy or lactation (although unlikely in this population)
  • Participation in another clinical trial or investigational drug within the past 30 days
  • Active use of illicit substances or non-prescribed psychoactive drugs within the past 30 days.
  • Severe dementia due to Alzheimer's disease or another etiology
  • Physical or mental impairment that prevents the participant from complying with the cognitive testing battery.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-11-19

View full record on ClinicalTrials.gov

All APOE4 clinical trials